SLC6A4
ENSG00000108576
Target class
Transporter
Chromosome
17
Approved drugs
32
Clinical candidates (approved and in development)
45
- Approved drugs
- 32
- ClinGen gene-disease validity
- Disputed
- Clinical candidates (approved and in development)
- 45
- Chemical probe available
- Yes
- Target name
- SLC6A4
- Gene name
- Solute carrier family 6 member 4
- Gene symbol
- SLC6A4
- Protein name
- Sodium-dependent serotonin transporter (SERT) (5HT transporter) (5HTT) (Solute carrier family 6 member 4)
- 5-HTT
- SERT1
- HTT
- OCD1
- Gene biotype
- Protein coding
- Gene family
- Solute carrier family 6
- Target class
- Transporter
- Target type
- Human gene
- Tissues expressed in
- 4
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 35.74
- Tissue specificity (Gini)
- 0.833
- Tissue specificity (tau)
- 0.99
- KEGG gene identifiers
- hsa:6532
- Protein interaction confidence
- 0.838
- Protein interaction partners
- 31
- R-HSA-380615
- R-HSA-442660
- End position
- 30238482
- Start position
- 30194312
- Chromosome
- 17
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein . Endomembrane system
- Multi-pass membrane protein . Endosome membrane
- Multi-pass membrane protein . Synapse . Cell junction, focal adhesion . Cell projection, neuron projection . Note=Could be part of recycling endosomes (PubMed:16870614). Density of transporter molecules on the plasma membrane is itself regulated by STX1A (By similarity). Density of transporter molecules on the plasma membrane is also regulated by serotonin (PubMed:17506858). Density of transporter molecules seems to be modulated by ITGAV:ITGB3 (By similarity). .
- Golgi apparatus
- Vesicles
- PubMed 12869649
- PubMed 16870614
- PubMed 17506858
- PubMed 27049939
- Tissue specificity (tau)
- 0.99016
- Expression inequality (Gini)
- 0.832727
Expression in transcripts per million
- Lung
- 35.74
- Small Intestine - Terminal Ileum
- 4.22
- Cells - EBV-transformed lymphocytes
- 1.78
- Esophagus - Mucosa
- 1.65
- Nerve - Tibial
- 0.73
Expression in transcripts per million
- Lung35.74
- Small Intestine - Terminal Ileum4.22
- Cells - EBV-transformed lymphocytes1.78
- Esophagus - Mucosa1.65
- Nerve - Tibial0.73
- Testis0.69
- Skin - Sun Exposed (Lower leg)0.68
- Artery - Aorta0.57
- Skin - Not Sun Exposed (Suprapubic)0.53
- Brain - Cerebellar Hemisphere0.45
- Heart - Atrial Appendage0.38
- Brain - Cerebellum0.38
- Vagina0.37
- Fallopian Tube0.31
- Thyroid0.3
- Breast - Mammary Tissue0.28
- Adipose - Subcutaneous0.28
- Spleen0.25
- Adipose - Visceral (Omentum)0.23
- Artery - Coronary0.23
- Esophagus - Gastroesophageal Junction0.23
- Esophagus - Muscularis0.21
- Kidney - Cortex0.21
- Colon - Transverse0.2
- Kidney - Medulla0.19
And 29 more, listed on the interactive page.
- GO:0006836
- GO:0009636
- GO:0051610
- GO:0090067
- GO:0005794
- GO:0005886
- GO:0010008
- GO:0012505
- GO:0045121
- GO:0005178
- GO:0005335
- GO:0005515
- GO:0008504
- GO:0015297
- GO:0031402
- GO:0051378
nausea and vomiting
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: nausea and vomiting
- cardiovascular system
- nervous system
- gastrointestinal
Evidence sourceinsomnia
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: insomnia
- cardiovascular system
- nervous system
- gastrointestinal
Evidence sourcepulmonary hypertension
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: pulmonary hypertension
- central nervous system
- cardiovascular
- gastrointestinal
- blood
PubMed 28216264Decrease, Population growth rate
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Evidence sourcegastrointestinal cramps
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: gastrointestinal cramps
- cardiovascular system
- nervous system
- gastrointestinal
Evidence sourcedizziness
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: dizziness
- central nervous system
- cardiovascular
- gastrointestinal
- blood
PubMed 28216264Decreased, Reproductive Success
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Evidence sourcedecreased/increased anxiety
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased/increased anxiety
- central nervous system
- cardiovascular
- gastrointestinal
- blood
PubMed 28216264sexual dysfunction
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: sexual dysfunction
- cardiovascular system
- nervous system
- gastrointestinal
Evidence sourcediarrhea
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: diarrhea
- central nervous system
- cardiovascular
- gastrointestinal
- blood
PubMed 28216264decreased/increased locomotor activity
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased/increased locomotor activity
- central nervous system
- cardiovascular
- gastrointestinal
- blood
PubMed 28216264decreased eating
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased eating
- central nervous system
- cardiovascular
- gastrointestinal
- blood
PubMed 28216264nausea
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: nausea
- central nervous system
- cardiovascular
- gastrointestinal
- blood
PubMed 28216264Increased, Reproductive Success
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Evidence sourcedecreased platelet aggregation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased platelet aggregation
- central nervous system
- cardiovascular
- gastrointestinal
- blood
PubMed 28216264Increase, predation
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Evidence sourceIncreased, predation
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Evidence sourcedry mouth
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: dry mouth
- central nervous system
- cardiovascular
- gastrointestinal
- blood
PubMed 28216264primary pulmonary hypertension
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: primary pulmonary hypertension
- cardiovascular system
- nervous system
- gastrointestinal
Evidence sourceDecrease, Population growth rate
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Evidence sourcedecreased body weight
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased body weight
- central nervous system
- cardiovascular
- gastrointestinal
- blood
PubMed 28216264valvular heart disease
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: valvular heart disease
- cardiovascular system
- nervous system
- gastrointestinal
Evidence sourceanxiety
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: anxiety
- cardiovascular system
- nervous system
- gastrointestinal
Evidence sourcediarrhea
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: diarrhea
- cardiovascular system
- nervous system
- gastrointestinal
Evidence sourcedecreased appetite
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased appetite
- central nervous system
- cardiovascular
- gastrointestinal
- blood
PubMed 28216264
And 8 more, listed on the interactive page.
increased gastrointestinal motility
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: increased gastrointestinal motility
- cardiovascular system
- central nervous system
PubMed 23197038decreased upper gastrointestinal transit
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: decreased upper gastrointestinal transit
- cardiovascular system
- central nervous system
PubMed 23197038insomnia
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: insomnia
- cardiovascular system
- central nervous system
PubMed 23197038increased other serotonin-mediated effects
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: increased other serotonin-mediated effects
- cardiovascular system
- central nervous system
PubMed 23197038sexual dysfunction
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: sexual dysfunction
- cardiovascular system
- central nervous system
PubMed 23197038nausea
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: nausea
- cardiovascular system
- central nervous system
PubMed 23197038decreased plasma renin
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: decreased plasma renin
- cardiovascular system
- central nervous system
PubMed 23197038anxiety
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: anxiety
- cardiovascular system
- central nervous system
PubMed 23197038receptor binding
Studies
- biochemical: NVS_TR_hSERT, is one of one assay component(s) measured or calculated from the NVS_TR_hSERT assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.
Biological samples
- vascular, tissue-based cell-free
Evidence source
Related records
Trials (2,158)
- 'Fix the Dysfunction' Concept for Mechanism-based Pharmacological Treatment of Neuropathic Pain by Drug
- "Evaluation by Transcranial Magnetic Stimulation of the Benefit of Fluoxetine on Motor Recovery After Stroke"
- "MILNACIPRAN" in Subjects With Chronic Shoulder Pain
- 12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder
- 16-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Bipolar Depression
- 24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
- 48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)
- 6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder
- 7T Amygdala and Citalopram Study
- 90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions
- 90 mg Fluoxetine Hydrochloride Capsules Under Non-Fasting Conditions
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
- A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder
- A 52-Week Study of Bicifadine in Patients With Chronic Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
- A 6 Week Study to Determine the Effectiveness of R228060 in Adult Subjects With Major Depressive Disorder
- A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets
- A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD
- A Clinical Study in Healthy Women Which Aims to Explore the Intestinal Uptake of Two Different Tablets of GRTA9906 Into the Body and the Effect of Food on it
Drugs (68)
- Amitifadine Monoamine transporter inhibitor
- Amitriptyline Serotonin transporter inhibitor
- Amitriptyline hydrochloride Serotonin transporter inhibitor
- Amoxapine Serotonin transporter inhibitor
- Bicifadine Monoamine transporter inhibitor
- Centanafadine Monoamine transporter inhibitor
- Chlorphentermine Serotonin transporter substrate
- Chlorphentermine hydrochloride Serotonin transporter substrate
- Citalopram Serotonin transporter inhibitor
- Citalopram hydrobromide Serotonin transporter inhibitor
- Clomipramine Serotonin transporter inhibitor
- Clomipramine hydrochloride Serotonin transporter inhibitor
- Dapoxetine Serotonin transporter inhibitor
- Dasotraline Monoamine transporter inhibitor
- Desvenlafaxine Serotonin transporter inhibitor
- Desvenlafaxine fumarate Serotonin transporter inhibitor
- Desvenlafaxine succinate Serotonin transporter inhibitor
- Dothiepin Serotonin transporter inhibitor
- Duloxetine Serotonin transporter inhibitor
- Duloxetine hydrochloride Serotonin transporter inhibitor